...We Welcome You To The Resverlogix HUB withIn The AGORACOM COMMUNITY!

Free
Message: Session LBS.01 - Late Breaking Science I: Outside the Box: New Approaches to CVD Risk Reduction
Effect of BET Protein Inhibition With Apabetalone on Cardiovascular Outcomes in Patients With Acute Coronary Syndrome and Diabetes - Results of the BETonMACE Trial
 
 November 16, 2019, 11:42 AM - 11:50 AM  Main Event I
Keywords BET inhibition,Epigenetics,Cardiovascular outcomes,,
Authors Kausik K Ray, Imperial Coll London, London, United Kingdom; Stephen J Nicholls, Monash Univ, Melbourne, Australia; Henry N Ginsberg, Columbia Univ, New York, NY; Jan O Johansson, Resverlogix Corp, Calgary, AB, Canada; Kamyar Kalantar-Zadeh, Univ of California Irvine, Orange, CA; Ewelina Kulikowski, Resverlogix Corp, Calgary, AB, Canada; Peter P. Toth, Univ of Illinois Coll of Med, Peoria, IL; Norman Wong, Michael Sweeney, Resverlogix Corp, Calgary, AB, Canada; Gregory G Schwartz, VA Eastern Colorado Healthcare System, Aurora, CO; BETonMACE Investigators Disclosures K.K.Ray: Honoraria; Modest; Amgen, Sanofi, Regeneron, Esperion, Medicines Company, Boehringer Ingelheim, Novo Nordisk, Kowa, Resverlogix, Dr Reddys, Cipla, Algorithm, Zuelling Pharma, Silence Therapeutics, Cerenis, Lilly, Astra Zeneca, Bayer, Akcea, MSD, Novartis, Research Grant; Significant; Amgen, Sanofi, Regeneron, MSD, Pfizer. G.G.Schwartz: Other Research Support; Modest; The Medicines Company, Other Research Support; Significant; Resverlogix, Sanofi, Research Grant; Significant; Roche. Betonmace investigators: n/a. S.J.Nicholls: Honoraria; Modest; AstraZeneca, Akcea, Eli Lilly, Anthera, Omthera, Merck, Takeda, Resverlogix, Sanofi-Regeneron, CSL Behring, Esperion and Boehringer Ingelheim, Research Grant; Significant; AstraZeneca, Amgen, Anthera, Eli Lilly, Esperion, Novartis, Cerenis, The Medicines Company, Resverlogix, InfraReDx, Roche, Sanofi-Regeneron and Liposcience. H.N.Ginsberg: Honoraria; Modest; Resverlogix. J.O.Johansson: Employment; Significant; Resverlogix . K.Kalantar-zadeh: Honoraria; Modest; Honoraria and/or support from Abbott, Abbvie, Akebia, Alexion, Amgen, ASN (American Society of Nephrology), Astra-Zeneca, Aveo, BBraun, Chugai, Daiichi, DaVita, Fresenius, Genentech, Haymarket Media, , Other Research Support; Modest; Honoraria and/or support from Abbott, Abbvie, Akebia, Alexion, Amgen, ASN (American Society of Nephrology), Astra-Zeneca, Aveo, BBraun, Chugai, Daiichi, DaVita, Fresenius, Genentech, Haymarket Media, . E.Kulikowski: Employment; Significant; Resverlogix Corp, Stock Shareholder; Significant; Resverlogix Corp. P.P.Toth: Other - Consulting; Modest; Amgen, Novo-Nordisk, Resverlogix, Theravance, Other - Consulting; Significant; Amarin, Kowa, Speaker/Speaker's Bureau; Modest; Merck, Sanofi, Speaker/Speaker's Bureau; Significant; Amarin, Amgen, Novo-Nordisk, Regeneron. N.Wong: n/a. M.Sweeney: Employment; Significant; Resverlogix. Abstract Abstract embargoed at this time.
Share
New Message
Please login to post a reply